Part 11: Novartis: PETA Names the 10 Worst CEOs for Animals in
Laboratories
Despite thousands of dead animals and millions of dollars spent by
Novartis and its subsidiaries to develop animal organs for
transplantation into humans, the company will never be able to
transplant a soul or any compassion into CEO Paulo Costa. Pointless
and painful experiments in xenotransplantation=97transplanting the
organs of one species into another species=97have been one of the
greatest medical disasters of all time.
Peddling transgenic pig parts and other organs designed to replace
human parts is very profitable. The fact that these transplants are
prohibitively expensive, of limited value, and always deadly hasn't
slowed Costa's search for an immunopig.
Six thousand people are on waiting lists for human organs; while the
problem of organ shortage could largely be solved through default
consent to organ donation when people die, the use of animals as
warehouses for spare parts continues. One hundred years of failed
research shows that animals=97even if they have transplanted human
genes=97
do not have suitable spare parts for humans. Pigs are now being
genetically manipulated to carry human genes in the hope that this
catalog of failure and misery can be turned into a viable form of
medical treatment. Other animals=97such as hamsters, rabbits, and monkeys
=97have also been subjected to horrific and pointless transplantation
experiments. But animals were never meant to be wrecking yards for
human parts. All attempts to carry out animal-to-human organ
transplants have failed. These surgeries are so monumentally
unsuccessful that the animals usually begin to die within minutes of
receiving an organ.
In Novartis' experiments, monkeys have endured lethal infections,
lethal blood clotting, bleeding complications, viral and protozoal
infections, lymph cancer, severe nausea, severe stomach inflammation
and diarrhea, dehydration, fatal pneumonia, persistent wound
infections, breakdowns, brain trauma, heart attacks, pneumonia, and
anemia. Huge doses of immune-suppressing drugs have caused internal
hemorrhaging.
A swab left in a monkey's abdomen by a Novartis employee caused a
lethal infection, and similar incidents occurred on a regular basis.
Sometimes the hearts or kidneys would simply not function after
transplantation, and some pig organs were rejected almost
instantaneously, undermining the only difference between genetically
modified pigs and normal pigs. Victims of these gruesome experiments
were overdosed with anesthetics, and their spleens were removed. One
pig's kidney was accidentally transplanted into the abdomen of a
monkey, and the primate died shortly afterward. If monkeys and baboons
survived surgery, they faced death by organ rejection and failure,
infections resulting from drug toxicity, or severely impaired immune
systems.
The danger isn't only a risk for the animals used in the experiments.
Some viruses carried by animals are impossible to eradicate and can
infect humans=97potentially with catastrophic results, such as the
deadly influenza epidemic of 1918 that killed millions of people, mad
cow disease, HIV, and the recent avian flu epidemic. This threatens
human patients who would receive pig organs, and scientists across the
globe are concerned that these viruses may pass into the general
population, causing an epidemic that could affect all of us.
Write to Costa, and let him know that Novartis' preposterous venture
will never result in cures for ailing and aging humans:
Paulo Costa, CEO
Novartis Cor****ation
608 Fifth Ave.
New York, NY 10020
http://www.stopanimaltests.com/f_ten_worst_ceo.asp
Here is one of the crimes committed to monkeys. Note: This research,
if you can call this torture anything like that, is simply done to
speed up worldwide use of cyclos****ine. Most of the output is produced
at Sandoz Kundl in Austria. 98% of the cyclos****ine produced in Kundl
is ex****ted.
Title
Pharmacokinetics of cyclos****ine in monkeys after oral and
intramuscular administration: relation to efficacy in kidney
allografting
H.-J. Schuurman, K. Mennninger, M. Odeh, W. Slingerland, M. Ossevoort,
M. Jonker, J.-C. Hengy, B. Dorobek, J. Vonderscher, J. Ringers, H.-J.
Schuurman (2001) Pharmacokinetics of cyclos****ine in monkeys after
oral and intramuscular administration: relation to efficacy in kidney
allografting
Transplant International 14 (5) , 320=96328 doi:10.1111/j.
1432-2277.2001.tb00066.x
Abstract
In cynomolgus and rhesus monkeys, the dose-normalized exposure of
cyclos****ine administered orally as microemulsion preconcen-trate
(Neoral) was lower than that upon intramuscular administration. For
oral administration, mean values (=B1 SD) of Cmax, 24-h area-under-the
curve (AUC) and 24-h trough level, all normalized for a 1 mg/kg dose,
were 20 =B1 9 ng kg/mg ml, 210 =B1 70 ng h kg/mg ml and 2.6 =B1 0.9 ng
kg/mg=
ml, respectively. For intramuscular administration, levels were about
5.5-fold, 9-fold and 22-fold higher. Based on phar-macokinetic data,
the efficacy of oral cyclos****ine treatment (without any other
immunosuppressant) was evaluated in life-sup****ting cynomolgus monkey
kidney allotransplantation. Rejection-free kidney allograft survival
could be achieved using oral cyclos****ine monotherapy with average 24-
h trough concentrations above 100 ng/ml during maintenance treatment.
Typically, daily oral doses of 100 mg/kg-150 mg/kg during the first
two weeks post-transplantation, followed by daily 30 mg/kg-100 mg/kg
dose levels during subsequent maintenance can result in long-term
allograft survival, with 24-h average trough levels in individual
animals during maintenance between 110 ng/ml and 700 ng/ml.
Place
The experiments took place at the BPRC Biomedical Primate Research
Centre, Rijswijk, The Netherlands
The =84researching=93 torturers
* H.-J. Schuurman, 1Transplantation Research, Novartis Pharma AG, 4002
Basel, Switzerland
* K. Menninger, 1Transplantation Research, Novartis Pharma AG, 4002
Basel, Switzerland
* M. Odeh, 1Transplantation Research, Novartis Pharma AG, 4002 Basel,
Switzerland
* W. Slingerland, 2Biomedical Primate Research Centre, 2280 GH
Rijswijk, The Netherlands
* M. Ossevoort, 2Biomedical Primate Research Centre, 2280 GH Rijswijk,
The Netherlands
* M. Jonker, 2Biomedical Primate Research Centre, 2280 GH Rijswijk,
The Netherlands
* J.-C. Hengy, 3Department of Drug Metabolism and Pharmacokinetics,
Novartis Pharma AG, 4002 Basel, Switzerland
* B. Dorobek, 3Department of Drug Metabolism and Pharmacokinetics,
Novartis Pharma AG, 4002 Basel, Switzerland
* J. Vonderscher, 3Department of Drug Metabolism and Pharmacokinetics,
Novartis Pharma AG, 4002 Basel, Switzerland
* J. Ringers, 4Department of Surgery, Leiden University Medical
Center, Leiden, The Netherlands
* H.-J. Schuurman, 5Immerge BioTherapeutics, Building 75, 3rd Avenue,
Charlestown, MA02129, USA
1Transplantation Research, Novartis Pharma AG, 4002 Basel, Switzerland
2Biomedical Primate Research Centre, 2280 GH Rijswijk, The Netherlands
3Department of Drug Metabolism and Pharmacokinetics, Novartis Pharma
AG, 4002 Basel, Switzerland
4Department of Surgery, Leiden University Medical Center, Leiden, The
Netherlands
5Immerge BioTherapeutics, Building 75, 3rd Avenue, Charlestown,
MA02129, USA
Contact
henk.schuurman@[EMAIL PROTECTED]
+1-617-241-5565
Fax +1-617-241-0539
More Novartis Crimes:
inform the public about more scandals of Novartis
http://groups.google.com/group/novartis-crimes
More about Novartis:
http://www.novartiskills.eu
A.L.F. Crime Investigation Agency (CIA)
alfcia_vries@[EMAIL PROTECTED]
|
